+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

Janssen Announces U.S. FDA Approval of SYMTUZA, the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved…

read more

Third Novartis Phase III trial shows Kisqali (ribociclib) combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Novartis has announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3…

read more

FDA approves TPOXX (tecovirimat) the first drug with an indication for treatment of smallpox

The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox.…

read more

Veyvondi, vonicog alfa, for the treatment of Willebrand disease.

On 28 June 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more

Verkazia, (ciclosporin), new medicine for rare form of eye allergy in children and teenagers

The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the European Union (EU) for Verkazia (ciclosporin), a medicine that…

read more

Genentech Announces Submission of Supplemental New Drug Application for Venclexta (venetoclax) for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

Genentech has announced submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Venclexta (venetoclax),…

read more

FDA approves encorafenib and binimetinib (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for unresectable or metastatic melanoma with BRAF mutations

On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in…

read more

Ulipristal Acetate, a pre-operative treatment of uterine fibroids, gets a positive opinion from the Committee for Medicinal Products for Human Use (CHMP)

On 28 June 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more

FDA approves Doptelet ( avatrombopag) for patients with chronic liver disease who have low blood platelets and are undergoing a medical procedure

The U.S. Food and Drug Administration has approved Doptelet (avatrombopag) tablets to treat low blood platelet count (thrombocytopenia) in adults…

read more

FDA APPROVES XEOMIN (INCOBOTULINUMTOXINA) FOR ADULT PATIENTS WITH SIALORRHEA

The FDA has approved the supplemental Biologics License Application (sBLA) for XEOMIN (incobotulinumtoxinA) for the treatment of chronic sialorrhea, or excessive…

read more

First two CAR-T cell medicines, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) recommended for approval in the European Union

The European Medicines Agency (EMA) has recommended the first two marketing authorisations for chimeric antigen receptors (CAR) T-cells medicines in the European Union…

read more

Xeljanz (tofacitinib citrate) receives marketing authorisation in the EU for active Psoriatic Arthritis

The European Commission has approved XELJANZ (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the…

read more

CONTACT US

ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message

captcha